ADIM
ICPT

Alpha DNA Investment Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Alpha DNA Investment Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-55
Closed -$1K – 711
2021
Q1 		$1K Sell
55
-22,203
-100% -$619K ﹤0.01% 669
2020
Q4 		$549K Buy
+22,258
New +$738K 0.59% 82

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Alpha DNA Investment Management's ICPT Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2021, closing a stake of 55 shares — an estimated $1K sold.

Alpha DNA Investment Management first reported a position in ICPT in Q4 2020 and held it in 2 quarters. The position peaked at $549K in Q4 2020. 129 funds tracked by Wall St. Rank hold ICPT as of Q2 2021.

  • Alpha DNA Investment Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 55 Intercept Pharmaceuticals, Inc. shares in Q2 2021, an estimated $1K.
  • Alpha DNA Investment Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2020 and held it in 2 quarters.
  • Alpha DNA Investment Management's Intercept Pharmaceuticals, Inc. position peaked at $549K in Q4 2020.
  • 129 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.